JPRN-UMIN000004796招募中2 期
Phase II Study of cisplatin plus irinotecan for large cell neuroendocrine carcinoma - Phase II Study of cisplatin plus irinotecan for large cell neuroendocrine carcinoma
ational Cancer Research Center Hospital East0 个研究点目标入组 44 人开始时间: 2010年12月27日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 44
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) unresectable disease with indication for chest radiotherapy 2) uncontrolled pleural/pericardial effusion 3) active concomitant malignancy 4) interstitial pneumonia or pulmonary fibrosis as determined by chest x-ray 5) watery diarrhea 6) intestinal obstruction or paralysis 7) symptomatic brain metastasis 8) severe complications: .uncontrolled angina, myocardial infarction within the previous 3 months, severe cardiac failure 9) pregnant or lactating women 10) psychological disease deemed unacceptable for inclusion to the study 11) severe drug allergy 12) doctor's decision not to be registered to this study
研究者
相似试验
已完成
2 期
phase II study of irinotecan plus cisplatin followed by amrubicin in patients with extensive disease small-cell lung cancer.extensive disease small-cell lung cancerJPRN-C000000113West Japan Oncology Group45
已完成
不适用
Phase II trial of irinotecan plus cisplatin for pretreated patients with Ewing sarcoma and PNETpretreated Ewing sarcoma or PNETJPRN-UMIN000001529ational cancer center hospital32
招募中
不适用
A phase II study of Irinotecan and cisplatin combination chemotherapy in metastatic, unresectable esophageal cancerNeoplasmsKCT0000670Seoul National University Hospital23
已完成
3 期
A Phase III Study Comparing Irinotecan, Cisplatin and Etoposide (PEI) with Nogitecan for the Treatment of Relapsed Small-Cell Lung Cancer (JCOG0605)Sensitive relpased small-cell lung cancerJPRN-UMIN000000828Japan Clinical Oncology Group(JCOG)180
已完成
2 期
Phase II study of nedaplatin plus irinotecan for stage III/IV squamous cell lung cancer (TORG0910)JPRN-UMIN000003330Thoracic Oncology Research Group (TORG)50